| GTO ID | GTC1571 |
| Trial ID |
NCT02625480
|
| Disease |
B-Cell Acute Lymphoblastic Leukemia
|
B-Cell Non-Hodgkin's Lymphoma
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | KTE-X19|Tecartus|Brexucabtagene autoleucel |
| Location approved | US, EU, UK, Australia, Canada |
| Generation | 2nd |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |
| Year | 2015 |
| Country | United States |
| Company sponsor | Kite, A Gilead Company |
| Other ID(s) | KTE-C19-104|2015-005010-30 |